Sign in

CIK 0001806310

  • Non-accelerated filer
  • Smaller reporting company

Taysha Gene Therapies, Inc.

Sign in to watch
Ticker
TSHA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
843199512
Phone
+1 214-612-0000
Business address
3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS, TX, 75247
  1. 4 Derivatives Options or other derivatives
  2. 3 Insider Initial Statement of Ownership
  3. 4 Planned sale Chief Financial Officer sold 33,000 shares at $2.33 ($76,890)
  4. 4 Open-market buy 10% owner bought 16,466,667 shares at $0.90 ($14,820,000)
  5. 4 Open-market buy Director bought 777,778 shares at $0.90 ($700,000)
  6. 4 Open-market buy Chief Executive Officer bought 444,444 shares at $0.90 ($400,000)
  7. 4 Open-market buy Director bought 111,111 shares at $0.90 ($100,000)
  8. 4 Open-market sale 10% owner sold 85,872 shares at an average $0.71 ($60,771)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 3 Insider Initial Statement of Ownership
  14. 4 Open-market sale 10% owner sold 28,608 shares at an average $0.70 ($20,119)
  15. 4 Open-market sale 10% owner sold 434,615 shares at an average $0.71 ($307,844)
  16. 4 Grant or award Chief Financial Officer acquired 6,230 shares (grant or award)
  17. 4 Open-market buy President and Head of R&D bought 5,000 shares at $0.68 ($3,400)
  18. 4 Other acquisition 10% owner acquired 251,296 shares (other)
  19. 4 Grant or award Chief Financial Officer acquired 18,691 shares (grant or award)
  20. 4 Derivatives Options or other derivatives

Page 3 of 6 · 120 filings